GlassScriptPhysician profile
Neel D Mehta
NPI 1760641161
$431,702.47
in general payments reported to CMS, 2019-2025
31 companies · $62K in 2025
The $62K reported for 2025 was more than what 98% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $22K · 2021: $47K · 2022: $75K · 2023: $78K · 2024: $79K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $43K · Honoraria: $22K · Consulting Fee: $17K · Travel and Lodging: $15K · Food and Beverage: $9,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,330.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $43,040.00 |
| Honoraria | $22,040.00 |
| Consulting Fee | $17,057.50 |
| Travel and Lodging | $15,014.61 |
| Food and Beverage | $9,906.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139,858.31 | 2019-2025 | Relistor |
| Boston Scientific Corporation | $104,501.06 | 2019-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, Intracept |
| Nevro Corp. | $56,255.61 | 2019-2023 | Omnia, Senza |
| Vertex Pharmaceuticals Incorporated | $34,643.10 | 2024-2025 | |
| Grt US Holding, INC. | $33,024.50 | 2021-2022 | |
| Averitas Pharma INC. | $26,166.72 | 2023-2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $13,880.92 | 2023 | Belbuca, Xtampza, Xtampza |
| Biodelivery Sciences International, INC. | $12,232.50 | 2019-2021 | |
| Medtronic, INC. | $2,863.50 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Abbott Laboratories | $1,243.55 | 2019-2024 | Eterna |
| Pacira Pharmaceuticals Incorporated | $1,076.12 | 2019-2023 | Exparel |
| Mml US, INC. | $971.84 | 2021-2023 | Reactiv8 |
| Vertos Medical, INC. | $812.50 | 2019-2020 | |
| Relievant Medsystems, INC. | $744.13 | 2021-2023 | Intracept |
| Stryker Corporation | $500.00 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $492.00 | 2019 | |
| Vertiflex, INC. | $429.19 | 2019 | |
| Biotronik Nro, INC. | $281.16 | 2024-2025 | Prospera |
| Saluda Medical Americas, INC. | $239.16 | 2023 | Evoke Scs |
| Appliedvr INC | $224.82 | 2025 | Relievrx |
| Stratus Medical, LLC | $210.40 | 2020-2023 | Nimbus |
| Medtronic USA, INC. | $193.45 | 2019-2020 | |
| Si-Bone, INC. | $164.01 | 2019-2020 | |
| Spr Therapeutics, INC | $148.99 | 2019-2025 | Sprint Pns System |
| Abbvie INC. | $146.77 | 2023 | |
| Nalu Medical, INC. | $125.88 | 2022 | |
| Siemens Medical Solutions USA, INC. | $92.95 | 2023 | |
| Foundation Fusion Solutions, LLC | $62.86 | 2025 | |
| Globus Medical, INC. | $55.09 | 2025 | Senza |
| Almatica Pharma LLC | $43.68 | 2021-2025 | Loreev Xr |
| Allergan, INC. | $17.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.